Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$6 Mln
P/E Ratio
--
P/B Ratio
0.52
Industry P/E
--
Debt to Equity
2.97
ROE
-1.85 %
ROCE
-115.16 %
Div. Yield
0 %
Book Value
0.18
EPS
-1.44
CFO
$-174.05 Mln
EBITDA
$-207.32 Mln
Net Profit
$-204.54 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Lyra Therapeutics Inc (LYRA)
| -58.09 | -49.71 | -53.77 | -98.40 | -77.42 | -- | -- |
|
BSE Sensex
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
|
|---|---|---|---|---|
|
Lyra Therapeutics Inc (LYRA)
| -95.96 | 66.88 | -27.98 | -61.75 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.19 | 10,117.70 | 20.54 | 23.13 | |
| 296.28 | 8,962.72 | 23.48 | 58.42 | |
| 24.72 | 9,739.03 | -- | -28.77 | |
| 101.38 | 9,903.71 | 30.43 | 14.16 |
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver... medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic rhinosinusitis (CRS); and LYR-220 for CRS patients who have failed previous medical management and continue to require treatment to manage CRS symptoms. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts. Address: 480 Arsenal Way, Watertown, MA, United States, 02472 Read more
Executive Chairman
Dr. Harlan W. Waksal M.D.
Executive Chairman
Dr. Harlan W. Waksal M.D.
Headquarters
Watertown, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Lyra Therapeutics Inc (LYRA) stood at $ 66 Mln as on 31-Dec-24
The share price of Lyra Therapeutics Inc (LYRA) is $0.09 (NASDAQ) as of 17-Apr-2025 16:05 EDT. Lyra Therapeutics Inc (LYRA) has given a return of -77.42% in the last 3 years.
Lyra Therapeutics Inc (LYRA) has a market capitalisation of $ 6 Mln as on 17-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Lyra Therapeutics Inc (LYRA) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Lyra Therapeutics Inc (LYRA) and enter the required number of quantities and click on buy to purchase the shares of Lyra Therapeutics Inc (LYRA).
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic rhinosinusitis (CRS); and LYR-220 for CRS patients who have failed previous medical management and continue to require treatment to manage CRS symptoms. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts. Address: 480 Arsenal Way, Watertown, MA, United States, 02472
The CEO & director of Dr. Harlan W. Waksal M.D.. is Lyra Therapeutics Inc (LYRA), and CFO & Sr. VP is Dr. Harlan W. Waksal M.D..
There is no promoter pledging in Lyra Therapeutics Inc (LYRA).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| Lyra Therapeutics Inc (LYRA) | Ratios |
|---|---|
|
Return on equity(%)
|
-184.99
|
|
Operating margin(%)
|
-3959.13
|
|
Net Margin(%)
|
-6090.94
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Lyra Therapeutics Inc (LYRA) was $0 Mln.
$-0.01
(
